Application of shikimic acid in preparing drug for preventing or treating demyelinating diseases

A demyelinating disease and shikimic acid technology, applied in the fields of bioengineering and medicine, can solve problems such as unreported application of shikimic acid, and achieve the effects of treating demyelinating diseases, promoting differentiation and maturation, and solving the failure of remyelination

Inactive Publication Date: 2018-08-10
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Currently, the application of shikimic acid in demyelinating diseases has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of shikimic acid in preparing drug for preventing or treating demyelinating diseases
  • Application of shikimic acid in preparing drug for preventing or treating demyelinating diseases
  • Application of shikimic acid in preparing drug for preventing or treating demyelinating diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Promoting effect of shikimic acid (SA) on the differentiation of oligodendrocyte precursor cells (OPCs).

[0033] 1. Experimental method:

[0034] In order to study and confirm the effect of shikimic acid on the differentiation of OPCs, qRT-PCR, Western blot, and immunocytochemistry were used to confirm that shikimic acid can promote the differentiation and maturation of OPCs from the mRNA level, protein level, and morphological level.

[0035] 1. Experimental cells: primary cultured oligodendrocyte precursor cells (OPCs).

[0036] 2. Experimental animals: Sprague-Dawley rats and C57BL / 6J mice used in this experiment were all purchased from Shanghai Xipuerbichem Laboratory Animal Co., Ltd.

[0037] 3. Reagents and consumables commonly used in the experiment: DMEM cell culture medium and Neurobasal / B27 culture medium were purchased from Gibco Company of the United States; fetal bovine serum FBS was purchased from PAA Company of Australia; 0.25% Trypsin trypsin, L-polyly...

Embodiment 2

[0069] Shikimic acid does not affect the proliferation and apoptosis of OPCs cultured in vitro

[0070] 1. Experimental method:

[0071] In order to verify that shikimic acid does not affect other changes in cells while promoting OPCs differentiation, BrdU binding assay and TUNEL assay were used to study cell proliferation and apoptosis, reflecting the effects of drugs on cells from two indicators.

[0072] 1. Experimental cells: primary cultured oligodendrocyte precursor cells (OPCs).

[0073]2. Experimental reagents, consumables and instruments: DMEM culture medium, Neurobasal / B27 were purchased from Gibco, USA; fetal bovine serum FBS was purchased from PAA, Australia; 0.25% Trypsin, L-polylysine (poly-L -lysine, PLL) was purchased from Sigma, USA. Other routine reagent materials in the laboratory were purchased from Shanghai Sinopharm Group, and cell culture dishes and plates were purchased from Corning Incorporated.

[0074] 3. Experimental drugs:

[0075] Medicine of ...

Embodiment 3

[0084] Shikimic acid alleviates disease state in EAE mice

[0085] 1. Experimental method:

[0086] In order to further verify the therapeutic effect of shikimic acid on demyelinating diseases, MOG 33-55 The EAE mouse model was induced, and the therapeutic administration was adopted, and the intraperitoneal administration was started on the 15th day after the model was established, once a day. After the modeling, the mice were observed every day until 25 days after the modeling.

[0087] 1. Experimental animals: C57BL / 6J adult female mice were purchased from Shanghai Slack Company. All animal experiments were performed in accordance with the animal management regulations and ethical requirements of the Animal Management Committee of the Naval Medical University of the Chinese People's Liberation Army.

[0088] 2. Experimental reagent: MOG 35-55 (GL Biochem), MTB (H37Ra strain; Difco), IFA (Incomplete Freund's adjuvant; Sigma-Aldrich), PTX (pertussis toxin; Difcolaboratorie...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of shikimic acid in preparing a drug for preventing or treating demyelinating diseases. In studying the effect of the shikimic acid in preventing or treating the demyelinating diseases, it is found that the shikimic acid can alleviate the severity of an inflammatory mouse demyelinating disease model induced by myelin sheath oligodendrocyte glycoprotein, improvethe demyelination lesion conditions of a focal mouse spinal cord demyelinating model induced by lysoph-osphatidylcholine, and accelerate remyelination and reduce the demyelination size by promoting oligodendrocyte progenitor cells to be differentiated into mature oligodendrocytes. As is shown by all above, the shikimic acid has a great application prospect in clinical treatment of the demyelinating diseases.

Description

technical field [0001] The invention belongs to the technical fields of bioengineering and medicine, and in particular relates to the application of shikimic acid in the preparation of drugs for preventing or treating demyelinating diseases. Background technique [0002] The demyelination injury of the central nervous system is widely found in many neurodegenerative diseases. If the demyelination injury is not repaired in time and effectively, it will not only affect the normal nerve conduction, but will further lead to the degeneration of nerve axons and Neurons die, triggering irreversible neurological dysfunction. At present, there is no exact and effective treatment for central demyelinating diseases, and it is very important to find suitable treatment strategies and targets. [0003] In the central nervous system, myelin refers to the cord-like outer membrane that surrounds sheathed nerve fibers. The central myelin sheath is an important structure composed of oligoden...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/19A61P25/00A61P25/28
CPCA61K31/19A61P25/00A61P25/28
Inventor 何成曹莉鲁凤凤浦颖艳
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap